# FFR and Acute Coronary Syndromes

William F. Fearon, MD

**Associate Professor** 


Director, Interventional Cardiology

Stanford University Medical Center



## **Increasing Prevalence of ACS**

144,039 Swedish patients (SCAAR Registry) undergoing PCI between 1990-2010





## **Increasing Prevalence of ACS**

 500,154 PCI's performed in the US between 2009-2010 were included in the NCDR

 71% of these procedures were in patients presenting with an acute coronary syndrome



### **Overview of FFR in ACS:**

- STEMI
  - Acute
  - Chronic
- Non-STEMI
  - Acute

- Culprit vessel
- Non-Culprit vessel



#### **Acute Microvascular Damage and FFR**

#### STEMI




Variable Degree of Reversible Microvascular Stunning



Maximum Achievable Flow is Less

With time, the microvasculature may recover, maximum achievable flow may increase, and a larger gradient with a lower FFR may be measured across a given stenosis



Smaller Gradient and Higher FFR across Any Given Stenosis



#### **Chronic Microvascular Damage and FFR**

Old Myocardial Infarction



Irreversible Microvascular
Damage



Maximum Achievable Flow is Less

In the setting of chronic microvascular dysfunction, the higher FFR is not falsely elevated, but reflects the smaller amount of viable myocardium supplied by the vessel and still provides information about the expected gain in flow after PCI





#### FFR in Acute STEMI (Culprit Vessel)

# FFR after stenting in 33 AMI patients compared to 15 stable angina patients

IVUS Parameters	AMI	Angina	P
Ref Lumen Area	7.45 ±2.4	6.49 ±1.6	NS
Min Lumen Area	5.28 ±1.7	5.03 ±1.1	NS
% Area Stenosis	27.3 ±9.3	25.76 ±13.1	NS
Pressure Parameter			
FFR	$0.95 \pm 0.04$	$0.90 \pm 0.04$	0.003



#### FFR in Acute STEMI (Culprit Vessel)

FFR after stenting in 33 AMI patients comparing those with TIMI 3 flow (n=23) to those with TIMI 2 flow (n=10)

IVUS Parameters	TIMI 3	TIMI 2	P
Ref Lumen Area	7.69 ±2.6	6.89 ±1.8	NS
Min Lumen Area	5.48 ±1.7	4.86 ±1.7	NS
% Area Stenosis	26.3 ±9.0	30.17 ±9.8	NS
Pressure Parameter			
FFR	0.93 ±0.04	0.98 ±0.02	<0.01



### FFR in Chronic MI (Culprit Vessel)

#### Changes in flow with and without microvascular dysfunction

	MI	No MI	P
Target lesion, n	22	21	
Pre-/postintervention, n	7/15	10/11	0.2
Diameter stenosis, %	$43 \pm 22$	$44 \pm 16$	0.9
MLD, mm	$1.7 \pm 0.8$	$1.6 \pm 0.6$	0.6
Length, mm	$9.1 \pm 4.0$	$7.3 \pm 3$	0.1
Reference diameter, mm	$2.9 \pm 0.5$	$2.8 \pm 0.6$	0.6
Flow velocity measurements			
APV (basal), cm/sec	$17 \pm 7$	$17 \pm 8$	0.8
APV (hyperemic), cm/sec	$26 \pm 13$	$36 \pm 16$	0.03
Coronary flow reserve	$1.5 \pm 0.3$	$2.1 \pm 0.4$	< 0.0001
Flow (hyperemic), ml/min	$37 \pm 26$	$48 \pm 22$	0.03
Pressure measurements			
Gradient (hyperemic), mm Hg	$13 \pm 11$	$21 \pm 13$	0.05
FFR, %	$82.6 \pm 12.5$	79.0 ± 11.7	0.3




#### FFR in ACS

How long do we have to wait after a STEMI before FFR can be reliably measured in the culprit vessel?




Comparison of FFR in 57 patients with an MI ≥ 6 days old to SPECT imaging before and after PCI





# Comparison of FFR in 57 patients with an MI ≥ 6 days old to SPECT imaging before and after PCI




	MIBI + n = 40	MIBI - n = 40
FFR≥0.75 n = 45	5	40
FFR<0.75 n = 35	35	0

Concordance = 94% $\kappa = 0.87$ ; P<0.0001




#### Ideal FFR cutoff in the setting of old MI






Relationship between FFR and mass of myocardium at risk





- FFR and SPECT performed in 48 patients 3.7 days after MI
  - □ 73% had STEMI and had to be ≥3 days; ≥2 days for NSTEMI
- 23 patients also had myocardial contrast echo
- Follow-up SPECT was performed 11 weeks later to identify true positive and negatives






True Reversible SPECT


True Fixed SPECT







#### Best FFR Cutoff is 0.78





#### FFR during/after STEMI (Culprit Vessel)

How long do you have to wait for "microvascular stunning" to resolve and before you can get a reproducible FFR?

Likely the time to recovery of the microvasculature is variable, depending on the size of the infarct, and can be as short as days, and as long as a week, or longer...




## FFR STEMI (Non-Culprit Vessels)

During acute STEMI, is FFR measurement of non-culprit vessels reliable?



#### FFR STEMI (Non-Culprit Vessels)

101 patients with an acute coronary syndrome (75 STEMI, 26 NSTEMI) 112 non culprit stenoses FFR measured acutely and 35±24 days later




In only 2/112 stenoses was the FFR >0.80 during the ACS and <0.75 at follow-up.



### FFR STEMI (Non-Culprit Vessels)

Microvascular resistance did not change from baseline to follow-up

#### **Index of Microcirculatory resistance**





# FFR during NSTEMI

- Can we measure FFR in non ST elevation acute myocardial infarction?
  - In the culprit vessel?
  - In the non-culprit vessel?



### FFR in NSTE ACS (Culprit Vessel)

# 70 patients with ACS and an intermediate lesion randomized to FFR or stress perfusion scan

	Group 1 (SPS) (n = 35)	Group 2 (FFR) (n = 35)
Age	55 ± 4	59 ± 6
Gender M/F	22/13	24/11
EF	$53 \pm 4$	50 ± 4
MI without ST-segment elevation (n)	24	20
ST-segment changes (n)	16	14
ST-segment changes or T-wave changes (n)	20	18
Prior coronary artery disease	14	9
Hypertension (n)	26	25
Diabetes mellitus (n)	11	13
Hyperlipidemia (n)	22	19
Tobacco abuse (n)	15	20
Lesion		
Left anterior descending (n)	13	15
Circumflex (n)	10	9
Right coronary artery (n)	12	11
Minimal lumen diameter (mm)	$1.51 \pm 0.1$	$1.43 \pm 0.1$
Reference lumen diameter (mm)	$3.1 \pm 0.2$	$2.88 \pm 0.2$
% Diameter stenosis	49 ± 2	$48 \pm 2$



## FFR in NSTE ACS (Culprit Vessel)

#### Clinical Events at 1 Year Follow-Up

	Group 1 (SPS) (n = 34)	Group 2 (FFR) (n = 34)
Average follow-up (months)	$12.0 \pm 0.8$	$14.0 \pm 1.0$
Death	0	0
Angina		
No angina (n)	17	24
CCS classification of angina (n)		
1–2	17	10
3-4 (admitted to the hospital)	6	5
Stress perfusion scintigraphy	4	4
Negative (n)	4	4
Cardiac catheterization	2	3
Results (no change)	2	2
Disease progression	0	1
MI	1	1
CABG including target vessel	1	2
PCI	0	0



### FFR NSTE ACS (Culprit + Non Culprit Vessel)

Fractional Flow Reserve *versus* 

Angiography for


Multivessel

**E**valuation





#### **FAME Trial:**






#### **Baseline Characteristics**

	Angio- Guided n = 496	FFR- Guided n = 509	P Value
Age, mean $\pm$ SD	64±10	65±10	0.47
Male, %	73	75	0.30
Diabetes, %	25	24	0.65
Hypertension, %	66	61	0.10
Current smoker, %	32	27	0.12
Hyperlipidemia, %	73	72	0.62
Previous MI, %	36	37	0.84
NSTE ACS, %	36	29	0.11
Previous PCI, %	26	29	0.34
LVEF, mean $\pm$ SD	57±12	57±11	0.92
LVEF < 50%, %	27	29	0.47


#### FFR NSTE ACS (Culprit + Non Culprit Vessel)

#### Comparison of MACE in FAME patients with and without ACS





#### What happens to deferred lesions?





### FFR in Acute Coronary Syndromes

#### Take Home Messages:

- FFR of the culprit vessel may be unreliable in the setting of STEMI, but can be accurately measured in the non-culprit vessel
- In a less acute MI setting, once microvascular stunning has decreased, FFR at a cut-point of 0.75-0.80 remains accurate
- For a given stenosis, FFR correlates inversely with the mass of viable myocardium supplied
- FFR appears accurate and safe in the setting of NSTE ACS for both culprit and non-culprit vessels



# Summary

#### Indications for FFR in Acute Coronary Syndromes

	Culprit Vessel	Non-Culprit Vessel
STEMI (acute)	-	+
STEMI (chronic)	+	+
Non ST Elevation ACS	+	+

